相关实验视频

Updated: Sep 19, 2025

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

编码SARS-CoV-2 Omicron XBB.1.5受体结合域的mRNA疫苗可以保护小鼠免受JN.1变种的侵害

Ryuta Uraki¹, Maki Kiso², Mutsumi Ito³

¹The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (The UTOPIA Center), Institutes for Advanced Study, University of Tokyo, Tokyo, 108-8639, Japan; International Virus Infectious Disease Research Center, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, 162-8655, Japan; International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo, 162-8655, Japan; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan.

|June 7, 2025

概括

使用XBB.1.5型LNP-mRNA-RBD的强剂疫苗有效地保护小鼠免受JN.1变种的侵害. 这种疫苗策略诱导了强烈的免疫反应,并减少了呼吸器官的病毒载荷,这表明它对新出现的SARS-CoV-2菌株有潜力.

科学领域:

病毒学病毒学
免疫学免疫学免疫学
疫苗学疫苗学疫苗学

背景情况:

SARS-CoV-2 Omicron JN.1 变种正在全球传播,引发了人们对疫苗有效性的担忧.
由于先前感染或接种疫苗,现有的免疫力可能无法完全保护新变种.
目前针对JN.1的mRNA疫苗的疗效需要进一步研究.

研究的目的:

评估XBB.1.5型LNP-mRNA-RBD疫苗作为针对SARS-CoV-2 JN.1变种的助推剂的免疫性和保护功效.
为了评估接种疫苗后的细胞和幽默免疫反应.
确定不同初级疫苗接种策略对对JN.1的增强的影响.

主要方法:

小鼠被免疫XBB.1.5型LNP-mRNA-RBD作为一个强剂疫苗.
分析了细胞和幽默免疫反应.
通过挑战免疫小鼠与JN.1变体并测量呼吸器官中的病毒负担来评估保护效果.

主要成果:

接种XBB.1.5型LNP-mRNA-RBD增剂疫苗诱导了针对XBB.1.5.5的特定中和活性和T细胞反应.
一种双价初级疫苗 (祖先+BA.4/5) 接着是XBB.1.5,与祖先增强相比,增强了对JN.1的交叉反应抗体.
基于XBB.1.5的LNP-mRNA-RBD增强疫苗接种在JN.1挑战后降低了呼吸器官中的病毒负担.

结论:

XBB.1.5型LNP-mRNA-RBD增强疫苗对抗原上不同的JN.1变种显示出有效性.
这些发现支持使用更新的mRNA疫苗来对抗新出现的SARS-CoV-2菌株.
优化的初级疫苗接种策略可以增强对新型变种的助推反应.

关键词:

在 LNP-mRNA-RBDD 中.鼠标模型模型奥米克朗 JN.1 变体这就是SARS-CoV-2病毒.

更多相关视频

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Engineering Antiviral Agents via Surface Plasmon Resonance

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

相关概念视频

Rab Proteins

Rab Proteins

Rab proteins constitute the largest family of monomeric GTPases, of which 70 members are present in humans. Rab proteins and their effectors regulate consecutive stages of vesicle transport such as vesicle transport, docking, and fusion to the correct recipient membrane.
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...